Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22319836 | 0.88 | TEAD1 (0.46) | YAP1KDM4E | |
| SCHEMBL3358504 | 0.87 | YAP1 (0.65) | YAP1PRMT5GPR119KDM4EPKM | |
| SCHEMBL30678895 | 0.86 | YAP1 (0.53) | YAP1CSF1RKDRPRMT5GPR119 | |
| SCHEMBL25383477 | 0.86 | YAP1 (0.53) | YAP1CSF1RKDRPRMT5GPR119 | |
| SCHEMBL30428901 | 0.84 | PRMT5 (0.50) | YAP1PRMT5CHEK2 | |
| SCHEMBL1646632 | 0.82 | GPR119 (0.59) | CSF1RKDRGPR119KDM4EPKM | |
| SCHEMBL12813454 | 0.80 | YAP1 (0.66) | YAP1PRMT5GPR119KDM4EPKM | |
| SCHEMBL13096956 | 0.79 | YAP1 (0.60) | YAP1CSF1RPRMT5GPR119KDM4E | |
| SCHEMBL6627883 | 0.79 | GPR119 (0.53) | YAP1PRMT5GPR119 | |
| SCHEMBL7326386 | 0.79 | GPR119 (0.61) | YAP1GPR119KDM4EPKMCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2023-12-05 | — | — | US | disclosed |
| EP-3700911-B1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2023-09-06 | — | — | EP | disclosed |
| CN-111511750-B | Macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2023-06-13 | — | — | CN | disclosed |
| EP-3700911-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier SAS (FR) | 2020-09-02 | — | — | EP | disclosed |
| CN-111511750-A | Novel macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2020-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833162-B2 | Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same | C1R, F12, RDX | YAP1 2354/4885CSF1R 1829/4885KDR 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.